<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Pluristem Therapeutics 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=15505></link><description><![CDATA[Pluristem Therapeutics 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Tue, 19 May 2026 05:36:25 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2011/06/12_238345340_20110620154204_1256661931.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Pluristem and United Therapeutics Enter Into an Exclusive License Agreement to Develop and Commercialize PLX Cells for the Treatment of Pulmonary Hypertension]]></title><link>https://www.newswire.co.kr/newsRead.php?no=552759</link><description><![CDATA[HAIFA, Israel--(Korea Newswire)--Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has entered into an exclusive out-license agreement with United Therapeutics Corporation (Nasdaq:UTHR) for the use of Pluristem's PLacental eXpanded (PLX) cells to develop and commercialize a cell-based product for the treatmen...]]></description><pubDate>Mon, 20 Jun 2011 17:00:00 +0900</pubDate></item></channel></rss>